Clinical trials: Extranodal NK/T-cell Lymphoma, open to volunteers
T-cell Non-Hodgkin Lymphoma, Lymphoma, Extranodal NK-T-Cell
Allogeneic Stem Cell Transplantation in Relapsed/Refractory T-, NK/T-cell Lymphomas
Relapsed and refractory T-cell lymphomas have been reported to have dismal outcomes. The role of allogeneic stem cell transplantation have been demonstrated in these patients.
- Trial name
- RRTCLAlloSCT (NCT02859402)
- Testing
- Busulfan, Fludarabine
- Where
- 2 sites in South Korea
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- Keimyung University Dongsan Medical Center
Extranodal NK/T-cell Lymphoma
BRIDGE-NK: Immunotherapy Versus Chemotherapy Induction Followed by Autologous HSCT in Advanced NKTCL
This is a randomized, open-label, prospective, multicenter phase III superiority study in patients with newly diagnosed stage IV extranodal NK/T-cell lymphoma.
- Trial name
- BRIDGE-NK (NCT07678229)
- Testing
- GELAD regimen, MEDA regimen, LEAP regimen
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Rong Tao
Chronic Myeloproliferative Disorders, Cognitive/Functional Effects
Registry of Older Patients With Cancer
RATIONALE: Gathering information about older patients with cancer may help the study of cancer in the future. PURPOSE: This research study is gathering information from older patients with cancer into a registry.
- Conditions
- Chronic Myeloproliferative Disorders, Cognitive/Functional Effects, Leukemia, Lymphoma
- Trial name
- NCT01137825
- Where
- 7 sites in United States
- Volunteers
- 3,000 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Extranodal NK/T-cell Lymphoma
Golidocitinib Combined With P-GemOx Plus PD-1 Inhibitor Versus P-GemOx Plus PD-1 Inhibitor in First-Line Newly Diagnosed Advanced or Non-Nasal Extranodal NK/T-Cell Lymphoma
This is a multicenter, randomized, Phase 2 clinical trial designed to evaluate the efficacy and safety of golidocitinib combined with the P-GemOx (pegaspargase + gemcitabine + oxaliplatin) regimen plus PD-1 inhibitor, compared…
- Trial name
- NCT07385989
- Testing
- Golidocitinib in combination with P-GEMOX and PD-1 inhibitor, PD-1 inhibitor in combination with P-GEMOX
- Volunteers
- 40 people
- Sponsor
- WEI XU
Extranodal Natural Killer T Cell Lymphoma
The Efficacy and Safety of Chidamide, Anti-PD-1 Antibody in Combination With Pegaspargase Versus DDGP in the Treatment of Newly Diagnosed, Stage III to IV Extranodal Natural Killer/T-Cell Lymphoma
A multicenter, prospective, randomized, open-label, controlled trial to evaluate the efficacy and safety of chidamide, anti-PD1 antibody, and pegaspargase versus dexamethasone, cisplatin, gemcitabine, and pegaspargase (DDGP) in…
- Trial name
- NCT06255795
- Testing
- chidamide, anti-PD1 antibody, and pegaspargase, DDGP
- Where
- China
- Volunteers
- 142 people
- Sponsor
- Ruijin Hospital
Natural Killer T-cell Lymphoma
Phase II Study of Golidocitinib and Benmelstobart in Patients with R/R ENKTL (JACKPOT50)
This is a prospective, single-arm, multicenter, phase II clinical trial to evaluate the efficacy and safety of golidocitinib and benmelstobart combination treatment in patients with relapsed or refractory extranodal natural…
- Trial name
- JACKPOT50 (NCT06733051)
- Testing
- Golidocitinib, Benmelstobart
- Where
- 2 sites in China
- Volunteers
- 47 people
- Sponsor
- Sun Yat-sen University
Extranodal NK T Cell Lymphoma, Hemophagocytic Lymphohistiocytosis (HLH)
Combination of Mitoxantrone Liposome and Etoposide, Dexamethasone, Pegaspargase and Golidocitinib (MEPL-G) in the Treatment of NK/T-cell Lymphoma Associated Hemophagocytic Lymphohistiocytosis (NKTCL-HLH)
Extranodal NK/T-cell lymphoma (NKTCL) is an aggressive EBV-associated lymphoma with poor prognosis, highly prevalent in China. Early-stage NKTCL achieves favorable long-term survival, while advanced disease shows dismal outcomes…
- Trial name
- NCT07525466
- Testing
- Mitoxantrone liposome, Etoposide, Pegaspargase (PEG) Asparaginase
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Beijing Tongren Hospital
Neoplasms
Phase 1 Study of JV-394 Autologous Anti-CD94 CAR T for r/r CD94+ T/NK Cell Neoplasms
The goal of this clinical research study is to find the highest tolerable dose of JV-394 (a type of autologous CAR-T cell therapy) that can be given to patients who have T/NK cell lymphoma that is relapsed or refractory.
- Trial name
- NCT07382817
- Testing
- JV-394
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- M.D. Anderson Cancer Center
Chronic Myeloproliferative Disorders, Leukemia
Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer
RATIONALE: Collecting and storing samples of tissue, blood, and body fluid from patients with cancer to study in the laboratory may help the study of cancer in the future.
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Lymphoproliferative Disorder
- Trial name
- NCT01137643
- Testing
- biologic sample preservation procedure, cytology specimen collection procedure
- Where
- United States
- Volunteers
- 15,000 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
nk/T-cell Lymphoma, Newly Diagnosed
Clinical Study of XPO1 Inhibitor Selinexor Combined With COPL in Newly Diagnosed Advanced NK/T-cell Lymphoma
Patients with newly diagnosed, pathologically confirmed NK/T-cell lymphoma of stage III-IV treated with XCOPL regimen. 3 weeks for a cycle, with a total of 6-8 cycles.
- Conditions
- nk/T-cell Lymphoma, Newly Diagnosed, Advanced Lymphoma
- Trial name
- NCT05833893
- Testing
- XPO1 inhibitor
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Chinese PLA General Hospital
NK/T Cell Lymphoma Nos
A Multicenter, Phase 3, Randomized Trial of Sequencial Chemoradiotherapy with or Without Toripalimab (PD-1 Antibody) in Newly Diagnosed Early-Stage Extranodal Natural Killer/T Cell Lymphoma, Nasal Type (ENKTL)
The purpose of this randomized, multi-center,phase Ⅲ clinical trail is to compare the safety and efficacy of sequencial chemoradiotherapy with or without toripalimab (PD-1 antibody) for newly diagnosed early-stage extranodal…
- Trial name
- NCT04365036
- Testing
- Toripalimab, Pegaspargase, Gemcitabine
- Where
- China
- Volunteers
- 207 people
- Sponsor
- Sun Yat-sen University
Extranodal NK/T-cell Lymphoma
Selinexor Combined With Reduced-Dose Radiotherapy For Early-Stage Extranodal NK/T-Cell Lymphoma
Extranodal NK/T-cell lymphoma (ENKTCL) is an Epstein-Barr virus-associated non-Hodgkin lymphoma with high incidence in Asia and Latin America.
- Trial name
- NCT07554482
- Testing
- Pegaspargase (PEG) Asparaginase, Gemcitabine (GEM), Oxaliplatin
- Where
- China
- Volunteers
- 34 people
- Sponsor
- Beijing Tongren Hospital
Complete Remission Rate， CRR, Progression Free Survival
Sintilimab, Chidamide, and Azacitidine for Untreated Stage I-II Extranodal NK/T-Cell Lymphoma
This is an open-label, single-arm, multi-center Phase II clinical trial evaluating the efficacy and safety of a novel sequential regimen as first-line therapy for treatment-naïve patients with Extranodal NK/T-cell Lymphoma…
- Conditions
- Complete Remission Rate， CRR, Progression Free Survival, Overall Survival, Adverse Event
- Trial name
- SCENT-3 (NCT07542912)
- Testing
- SCA Induction followed by Response-Adapted Therapy
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Sun Yat-sen University
T-NK Cell Lymphoma
The Value of PET Imaging Targeting Granzyme B in Predicting Efficacy and Prognosis in T-NK Cell Lymphoma
The study on the value of PET imaging targeting granzyme B in predicting the efficacy and prognosis of T-NK cell lymphoma.
- Trial name
- NCT06863441
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Ruijin Hospital
Extranodal NK/T-cell Lymphoma
Sintilimab, Pegaspargase Plus GemOx for Untreated Extranodal NK/T-Cell Lymphoma
This is a single-arm phase 2 study designed to evaluate the safety and efficacy of sintilimab, pegaspargase combined with gemcitabine and oxaliplatin (P-P-GEMOX regimen) as first-line treatment for patients with ENKTL.
- Trial name
- NCT06824883
- Testing
- Immunochemotherapy
- Where
- China
- Volunteers
- 49 people
- Sponsor
- Peking Union Medical College Hospital
Extranodal Natural Killer/T-cell Lymphoma
A Clinical Study of the Value of Circulating Free Methylated EBV DNA in Extranodal NK/T Cell Lymphoma
This study is a prospective, multicenter, open-label, single-arm clinical study. This study plans to enroll 72 newly diagnosed ENKTCL patients. The enrollment was completed in 2 years, and the follow-up was terminated in 4 years.
- Trial name
- NCT05343377
- Testing
- circulate free methylated EBV DNA
- Where
- China
- Volunteers
- 72 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
NK/T Cell Lymphoma
A Phase II Study of Dexamethasone, Azacitidine, Pegaspargase and Tislelizumab Plus Radiotherapy for Patients With Stage I/II Extranodal NK/T-cell Lymphoma
The goal of this clinical trial is to learn if the regimen of dexamethasone, azacitidine, pegaspargase and tislelizumab (DAPT regimen) combined with radiotherapy works to treat stage I or II NK/T cell lymphoma in adults.
- Trial name
- NCT07000617
- Testing
- DAPT regimen plus radiotherapy
- Where
- 3 sites in China
- Volunteers
- 57 people
- Sponsor
- Peking University Cancer Hospital & Institute
LGLL - Large Granular Lymphocytic Leukemia, Primary Cutaneous Gamma-Delta T-Cell Lymphoma
A Study of DR-01 in Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas
This is a multicenter, first-in-human, Phase 1/2 study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and anti-tumor activity of DR-01 in adult patients with large granular lymphocytic leukemia or…
- Conditions
- LGLL - Large Granular Lymphocytic Leukemia, Primary Cutaneous Gamma-Delta T-Cell Lymphoma, Primary Cutaneous CD8+ Aggressive Epidermotropic T-Cell Lymphoma, Hepatosplenic T-cell Lymphoma
- Trial name
- NCT05475925
- Testing
- DR-01
- Where
- 37 sites in United States, Australia and 7 more
- Volunteers
- 200 people
- Sponsor
- Dren Bio
Lymphoma, Extranodal NK-T-Cell
Selinexor, Anti-PD-1 Antibody Plus Golidocitinib in R/R NKTCL
A multicenter, prospective trial to evaluate the efficacy and safety of Selinexor, anti-PD-1 antibody plus Golidocitinib in the treatment of relapsed or refractory Natural Killer / T-cell lymphoma.
- Trial name
- NCT06573138
- Testing
- Selinexor, anti-PD-1 antibody plus Golidocitinib
- Volunteers
- 18 people
- Sponsor
- Ruijin Hospital
T-NK Cell Lymphoma
The Value of Artificial Intelligence-based 18F-FDG PET/CT in Diferential Diagnosis, Efficacy Prediction and Prognosis Prediction of T-NK Cell Lymphoma: a Clinical Study
Based on the PET/CT imaging data of patients with T-NK cell lymphoma, machine learning and deep learning methods are used to extract imaging features, establish a T-NK cell lymphoma prediction model, and provide more scientific…
- Trial name
- NCT06747299
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Ruijin Hospital